Table 7.
Effect of treatment exposure for combined sulforaphane (SF) and placebo (PL) groups at 15 weeks and for SF-only group at 30 weeks
| Biomarker | Intervention (exposure) | Change | ||
|---|---|---|---|---|
| N | F-statistic | p value | ||
| Free reduced GSHa | ||||
| 15 weeks | 40 | 1.95 | 0.170 | – |
| 30 weeks | 22 | 0.75 | 0.485 | |
| Total GSHa | ||||
| 15 weeks | 40 | 0.11 | 0.746 | – |
| 30 weeks | 22 | 0.06 | 0.946 | |
| GSSGa | ||||
| 15 weeks | 40 | 0.15 | 0.701 | ↑ |
| 30 weeks | 22 | 2.32 | 0.124 | |
| Free GSH:GSSG | ||||
| 15 weeks | 40 | 3.90 | 0.055 | ↓ |
| 30 weeks | 22 | 8.12 | 0.003 | |
| Total GSH:GSSG | ||||
| 15 weeks | 40 | 1.32 | 0.258 | ↓ |
| 30 weeks | 22 | 3.60 | 0.046 | |
Bold signifies p < 0.05
MANOVA test for repeated measures (compared to baseline at 0 weeks); analysis includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
aNatural log transformed